Nuclidium

Developer of novel radiopharmaceutical tracers designed to target cancer diagnostics. The company's platform provides new diagnostic and therapeutic tracers in which specific target molecules will fir...

Healthcare

Basel, Switzerland

Founded 2017

8 employees

Website

Valuation

$163.2M

Market implied

Share Price

N/A

Total Raised

$100.6M

Last Round

N/A

Investors

+13 other investors

View all 13 investors

Valuation History

0 funding rounds on record

Cap Table

Ownership structure

Market Activity

Secondary transactions

Get the full picture

Create a free account to unlock Nuclidium's funding history, team members, investor details, and more.

15 free profiles/month · No credit card required